Maze Therapeutics, Inc. (MAZE) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 South San Francisco, CA, 美国. 现任CEO为 Jason V. Coloma.
MAZE 拥有 IPO日期为 2025-01-31, 125 名全职员工, 在 NASDAQ Global Market, 市值为 $1.38B.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
